Accelerating Global Access to Gene Therapies
Gene therapies are reshaping modern medicine, but access remains an issue – especially in LMICs
Gene therapy is at the forefront of modern medicine. By making precise changes to the human genome, these sophisticated technologies can potentially lead to one-time lifelong cures. As of mid-2022, more than 2,000 gene therapies were in development worldwide, contributing to a global market value that is expected to reach nearly $20 billion by 2027.
Kevin worked with clinical leaders from across Tanzania, Uganda, South Africa, India, and Thailand, who are all actively engaged in gene therapy research, offering case studies comparing struggles and successes across multiple political economies. This white paper provides an overview of what is required to sustainably deliver gene therapies in LMICs, from preliminary R&D through clinical trials all the way to market access.
Articles
-
![]()
Gene therapy: Why we need to accelerate global access to the world’s most expensive drugs
WORLD ECONOMIC FORUM
-
![]()
What Does Global Health Justice Look Like With a Seven-Figure Drug?
SLATE
-
![]()
Gene therapy can make a real impact on global health but we need equitable access, say experts
WORLD ECONOMIC FORUM
-
![]()
New gene therapies may soon treat dozens of rare diseases, but million-dollar price tags will put them out of reach for many
THE CONVERSATION
-
![]()
8 things you should know about gene therapy
WORLD ECONOMIC FORUM
-
![]()
Making Gene Therapy Accessible
ISSUES IN SCIENCE AND TECHNOLOGY
Podcast
Gene therapy - how can poorer countries benefit from the most expensive drugs in the world?
Gene therapy is one of the fastest growing areas of healthcare with over 2,000 therapies in development globally. The new techniques could challenge some of the world’s most feared diseases, including HIV and cancer. But the enormous cost means poorer countries could miss out, and the fact that R&D is concentrated in richer countries means the therapies developed there might not always be suitable for use in other parts of the world.
This episode of the Radio Davos podcast hears from a senior healthcare figure in Uganda on what needs to be done.
Speakers:
Cissy Kityo, Executive Director of the Joint Clinical Research Centre in Uganda
Kevin Doxzen, Hoffmann Fellow, Precision Medicine and Emerging Biotechnologies, World Economic Forum